- Home
- MODD vs IMRX Comparison
MODD vs IMRX Comparison
Compare MODD & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- IMRX
- Stock Information
- Founded
- MODD 1998
- IMRX 2008
- Country
- MODD United States
- IMRX United States
- Employees
- MODD N/A
- IMRX N/A
- Industry
- MODD Industrial Specialties
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- IMRX Health Care
- Exchange
- MODD Nasdaq
- IMRX Nasdaq
- Market Cap
- MODD 55.3M
- IMRX 62.7M
- IPO Year
- MODD N/A
- IMRX 2021
- Fundamental
- Price
- MODD $1.00
- IMRX $1.14
- Analyst Decision
- MODD
- IMRX Strong Buy
- Analyst Count
- MODD 0
- IMRX 3
- Target Price
- MODD N/A
- IMRX $15.33
- AVG Volume (30 Days)
- MODD 95.0K
- IMRX 173.2K
- Earning Date
- MODD 06-20-2025
- IMRX 05-05-2025
- Dividend Yield
- MODD N/A
- IMRX N/A
- EPS Growth
- MODD N/A
- IMRX N/A
- EPS
- MODD N/A
- IMRX N/A
- Revenue
- MODD N/A
- IMRX N/A
- Revenue This Year
- MODD N/A
- IMRX N/A
- Revenue Next Year
- MODD N/A
- IMRX N/A
- P/E Ratio
- MODD N/A
- IMRX N/A
- Revenue Growth
- MODD N/A
- IMRX N/A
- 52 Week Low
- MODD $0.68
- IMRX $1.00
- 52 Week High
- MODD $2.65
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- MODD 52.36
- IMRX 37.54
- Support Level
- MODD $0.97
- IMRX $1.10
- Resistance Level
- MODD $1.15
- IMRX $1.30
- Average True Range (ATR)
- MODD 0.09
- IMRX 0.10
- MACD
- MODD 0.01
- IMRX -0.01
- Stochastic Oscillator
- MODD 50.00
- IMRX 9.76
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.